Close Menu

NEW YORK (GenomeWeb) — Biotheranostics announced today that its Breast Cancer Index (BCI) genomic test has has been issued an expanded local coverage determination (LCD) by Medicare contractor Noridian.

The PCR-based test evaluates the expression of 11 genes to help physicians predict the risk of late disease recurrence and identify which early-stage breast cancer patients are likely to benefit from continuing adjuvant endocrine therapy beyond five years.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.